中国神经再生研究(英文版) ›› 2017, Vol. 12 ›› Issue (6): 886-889.doi: 10.4103/1673-5374.208546

• 综述:神经损伤修复保护与再生 • 上一篇    下一篇

双重和多途径药物递送纳米粒子促进神经元存活和突触修复

  

  • 收稿日期:2017-05-22 出版日期:2017-06-15 发布日期:2017-06-15
  • 基金资助:

    此项研究由CNRS、捷克科学基金会GACR17-00973S、极光基础设施项目2期(CZ.02.1.01/0.0/0.0/15_008/0000162)和欧洲区域发展基金ELIBIO(CZ.02.1.01/0.0/0.0 /15_003 /0000447)共同赞助支持

Dual and multi-drug delivery nanoparticles towards neuronal survival and synaptic repair

Angelina Angelova1, Borislav Angelov2   

  1. 1 Institut Galien Paris-Sud, CNRS UMR 8612, University of Paris-Sud, Université Paris-Saclay, LabEx LERMIT, Châtenay-Malabry cedex, France; 2 Institute of Physics, ELI Beamlines, Academy of Sciences of the Czech Republic, Prague, Czech Republic
  • Received:2017-05-22 Online:2017-06-15 Published:2017-06-15
  • Contact: Angelina Angelova, Ph.D.,angelina.angelova@u-psud.fr.
  • Supported by:

    AA is supported by CNRS. BA is supported by the Czech Science Foundation Grant GACR 17-00973S and the projects ELI - Extreme Light Infrastructure – phase 2 (CZ.02.1.01/0.0/0.0/15_008/0000162) and ELIBIO (CZ.02.1.01/0.0/0.0/15_003/0000447) from the European Regional Development Fund.

摘要:

神经系统疾病的恢复疗法需要新的神经修复技术和策略刺激神经发生用以对抗衰老。由于神经退行性疾病是多因素的并且由多种危险因素引起,因此在后续疗法中针对单一途径机制通常不足以产生再生结果。大分子治疗剂(例如重组蛋白质、合成肽、单克隆抗体、质粒DNA、siRNA和CRISPR/Cas 9治疗剂)在用于基于神经再生纳米医学结构设计方面具有相当大的应用潜力。与传统的小有机分子药物相比,其中大部分大分子治疗剂预期在临床开发中的成功率将会更高。在大分子药物靶点中,脑源性神经营养因子(BDNF)及其高亲和力原肌球蛋白相关激酶受体(TrkB)对于针对神经元和突触修复的纳米医学改善呈现出强烈的兴趣。BDNF通过激活负责中枢和周围神经系统中神经元分化、增殖、可塑性、生长和存活的TrkB受体信号传导,参与神经元群体的发育和保护。这种神经营养因子会刺激神经发生的过程。BDNF还支持形成兴奋性和抑制性突触。增加的神经营养因子水平有利于通过长期增强强化现有的突触。因此,BDNF蛋白对于神经认知功能非常重要。此外,BDNF可激活翻译机制并刺激神经元中的新蛋白质合成。

ORCID:0000-0002-0285-0637(Angelina Angelova)

Abstract:

Among the macromolecular drug targets in neurodegenerative disorders, the neurotrophin brain-derived neurotrophic factor (BDNF) and its high-affinity tropomyosin-related kinase receptor (TrkB) present strong interest for nanomedicine development aiming at neuronal and synaptic repair. Currently, BDNF is regarded as the neurotrophic factor of highest therapeutic significance. However, BDNF has delivery problems as a protein drug. The enhanced activation of the transcription factor CREB (cAMP response element-binding protein) has been evidenced to increase the BDNF gene expression and hence the production of endogenous BDNF. We assume that BDNF delivery by nanocarriers and mitochondrial protection may provide high potential for therapeutic amelioration of the neuroregenerative strategies. Beneficial therapeutic outcomes may be expected for synergistic dual or multi-drug action aiming at (i) neurotrophic protein regulation in the central and peripheral nervous systems, and (ii) diminishment of the production of reactive oxygen species (ROS) and the oxidative damage in mitochondria. Our research strategy is based on a nanoarchitectonics approach for the design of nanomedicine assemblies by hierarchical self-assembly. We explore nanoarchitectonics concepts in soft-matter nanotechnology towards preparation of biodegradable self-assembled lipid nanostructures for safe neuro-therapeutic applications of multi-target nanomedicines.

Key words: BDNF delivery, neuroprotective lipid nanocarriers, neurotrophic factor, CREB, nanomedicine, macromolecular drugs, combination therapy